Garuda - Garba Rujukan Digital

Effect of Mannitol Hydration as Renoprotective on Cisplatin Induced Nephrotoxicity (CIN) in Head and Neck Cancer Patients Mareta Rindang, Andarsari; Yunita Dyah, Kusumaningrum; Rosy Nurlita, Hapsari; Dwi Hari, Susilo; Dewi Wara, Shinta
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 4 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i4.16958

Background: Cisplatin is a cytostatic agent used as treatments in head and neck cancer patients.Nephrotoxicity is one of cisplatin major side effects. This study aimed to evaluate the renoprotectiveeffect of mannitol-hydration administration in head and neck cancer patients who receive cisplatinchemotherapy. Methods: This was a cohort observational study to analyze the renal function of head andneck cancer patients who receives cisplatin before and after mannitol-hydration administration in IRNASurgery and Soekardja Room of Chemotherapy at RSUD Dr. Soetomo Surabaya during June – September2018. The data obtained were BUN, SCr, and eClCr Cockroft-Gault of each cycle. Result: A total of 52patients were evaluated. The average value of creatinine serum, creatinine clearance, and BUN at each cyclewere fluctuate. However, the average value of creatinine serum and BUN were within the normal limit.The result of statistical analysis using paired t-test in those parameters at each cycle were not statisticallysignificant (p > 0,05) after mannitol administration except during first cycle to second cycle the SCr increasedsignificantly and eClCr was decreased significantly (p-value 0,024; 0,006, CI 95% respectively ). At fourthcycle the eClCr also decreased significantly (p value 0,008, CI 95%). Conclusion: The renoprotective effectof mannitol in head and neck cancer patients who receive cisplatin chemotherapy is sufficiently adequatewhich can maintain the value of BUN and creatinine serum of patients at each cycle within the normal limit.

Efektivitas Profilaksis Primer Filgrastim Pada Pasien Kanker Payudara terhadap Insiden Neutropenia Andri Utomo; Widyati Widyati; Dwi Hari Susilo
MPI (Media Pharmaceutica Indonesiana) Vol. 3 No. 1 (2020): JUNE
Publisher : Fakultas Farmasi, Universitas Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24123/mpi.v3i1.2831

Kejadian febrile neutropenia menyebabkan penundaan jadwal kemoterapi, penurunan dosis kemoterapi, bahkan dapat menghentikan proses kemoterapi yang harus dijalani. Hal ini dapat berakibat pada penurunan tingkat keberhasilan terapi pada pasien kanker payudara. Kejadian neutropenia dapat dicegah dengan pemberian profilaksis primer granulocyte colony-stimulating factor (G-CSF), seperti filgrastim. Pemberian filgrastim dapat mengurangi risiko terjadinya febrile neutropenia, perawatan di Rumah Sakit, dan kematian pada pasien kanker payudara. Oleh karena itu, penelitian ini dilakukan untuk menganalisis efektivitas pemberian profilaksis filgrastim primer pada pasien kanker payudara yang mendapat kemoterapi. Penelitian ini merupakan jenis penelitian observasional analitik dengan rancang bangun prospective cohort study. Sampel yang digunakan yaitu 87 pasien kanker payudara yang sedang menjalani kemoterapi. Variabel yang diteliti adalah insiden neutropenia dan faktor risiko yang menyebabkan neutropenia. Hasil penelitian menunjukkan bahwa faktor risiko yang berpengaruh secara langsung terhadap insiden neutropenia adalah usia (p = 0,000), luas permukaan tubuh (p = 0,037), jenis kemoterapi (p = 0,000), siklus kemoterapi (p = 0,000), dan regimen kemoterapi (p = 0,000). Adanya profilaksis filgrastim primer efektif dalam menurunkan insiden neutropenia.

The Relationship between Recurrence Rate and Molecular Subtypes of Breast Cancer in Locally Advance Breast Cancer (LABC) Post Mastectomy: Focus on Comparison of Luminal A and Luminal B Eric Hartoyo Salim; Eddy Herman Tanggo; Dwi Hari Susilo
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 10 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i10.359

Background. Breast cancer is the highest prevalence of malignancy for women in Indonesia and important national health problem. Estimated 2 million women developed breast cancer in 2018 with a mortality rate of 14.1 in every 100,000 women. Regarding the relationship between subtypes and breast cancer recurrence Several studies on gene expression have shown several subtypes of breast cancer, including the two most important subtypes, estrogen receptor (ER) positive (Luminal A and Luminal B) and ER negative (Triple negative and Her2 positive). Based on the explanation above, currently there is no data in Soetomo Hospital that discusses the role of breast cancer subtypes as a prognostic factor in determining the recurrence rate in locally advanced breast cancer.Methods. The research design is an associative test using a retrospective cohort observational analytical study design, associating the relationship between tumor subtypes with recurrence in locally advanced breast cancer patients after mastectomy and has received additional therapy according to standard procedures at Dr. Soetomo Surabaya This study used secondary data from the medical records of the Oncology Polyclinic, RSUD Dr. Soetomo Surabaya from 2014 to 2019.Results. The research subjects who have been selected according to inclusion criteria are 214 people, with the proportion in the population of luminal A and luminal B subtypes of 107 people each. Based on this study, it was found that the subtype was positively correlated with recurrence in LABC patients who had undergonecmastectomy with a significance value of p = 0.000 (p <0.05; 99% CI).Conclusion. There is a relationship between the recurrence rate and the molecular subtype of breast cancer in locally advanced breast cancer (LABC) patients after mastectomy at Dr Soetomo Hospital.

The Relationship between Recurrence Rate and Molecular Subtypes of Breast Cancer in Locally Advance Breast Cancer (LABC) Post Mastectomy: Focus on Comparison of Luminal A and Luminal B Eric Hartoyo Salim; Eddy Herman Tanggo; Dwi Hari Susilo
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 10 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i10.359

Background. Breast cancer is the highest prevalence of malignancy for women in Indonesia and important national health problem. Estimated 2 million women developed breast cancer in 2018 with a mortality rate of 14.1 in every 100,000 women. Regarding the relationship between subtypes and breast cancer recurrence Several studies on gene expression have shown several subtypes of breast cancer, including the two most important subtypes, estrogen receptor (ER) positive (Luminal A and Luminal B) and ER negative (Triple negative and Her2 positive). Based on the explanation above, currently there is no data in Soetomo Hospital that discusses the role of breast cancer subtypes as a prognostic factor in determining the recurrence rate in locally advanced breast cancer.Methods. The research design is an associative test using a retrospective cohort observational analytical study design, associating the relationship between tumor subtypes with recurrence in locally advanced breast cancer patients after mastectomy and has received additional therapy according to standard procedures at Dr. Soetomo Surabaya This study used secondary data from the medical records of the Oncology Polyclinic, RSUD Dr. Soetomo Surabaya from 2014 to 2019.Results. The research subjects who have been selected according to inclusion criteria are 214 people, with the proportion in the population of luminal A and luminal B subtypes of 107 people each. Based on this study, it was found that the subtype was positively correlated with recurrence in LABC patients who had undergonecmastectomy with a significance value of p = 0.000 (p <0.05; 99% CI).Conclusion. There is a relationship between the recurrence rate and the molecular subtype of breast cancer in locally advanced breast cancer (LABC) patients after mastectomy at Dr Soetomo Hospital.

COMPARISON OF THE ANTIEMETIC EFFECTIVENESS BETWEEN GRANISETRON AND DEXAMETHASONE WITH ONDANSETRON AND DEXAMETHASONE IN ACUTE-PHASE CHEMOTHERAPY PATIENTS Arfiani, Ria Fitrah; Susilo, Dwi Hari; Suprapti, Budi
Folia Medica Indonesiana Vol. 52 No. 3 (2016): JULY - SEPTEMBER 2016
Publisher : Universitas Airlangga

Nausea and vomiting may occur in patients receiving chemotherapy, a condition referred to as chemotherapy-induced nausea and vomiting. The provision of combined dexamethasone and ondansetron or granisetron is the therapeutic management of acute phase nausea and vomiting in cytostatics with a high risk of nausea and vomiting. Granisetron has been known to have better pharmacokinetics and pharmacodynamics compared to ondansetron, so it is possible to have nausea and vomiting suppressing effect higher than that of ondansetron. This study aimed to compare antiemetic effectiveness of granisetron and dexamethasone with ondansetron and dexamethasone in acute-phase chemotherapy patients. This study was conducted in patients who received the combination of cisplatin-paclitaxel and cisplatin-fluorouracil, double-blind, with samples comprised new head and neck surgical oncology patients. Measurement of nausea and vomiting during the acute phase of chemotherapy was conducted using Index of Nausea, Vomiting, and Retching (INVR). Observation of nausea and vomiting in the patients was done during the first 12 hours after administration of cisplatin and interviews were conducted on h 12. Results showed that there was no difference in the effectiveness of nausea and vomiting suppression in the administration of granisetron and dexamethasone compared to ondanstron and dexamethasone in acute phase chemotherapy patients (p = 0.076).

ANALYSIS OF NACL-MANNITOL HYDRATION ON RENAL FUNCTION OF HEAD AND NECK CANCER PATIENTS RECEIVING HIGH-DOSE CISPLATIN CHEMOTHERAPY COMBINATION Desiani, Ekanita; Suharjono, Suharjono; Yulistiani, Yulistiani; Susilo, Dwi Hari
Folia Medica Indonesiana Vol. 53 No. 1 (2017): JANUARY - MARCH 2017
Publisher : Universitas Airlangga

Cisplatin is one of platinum cytostatic drug for the medication of solid cancers, one of which is head and neck cancer. Adverse event that resulted during drug treatment was acute or chronic nephrotoxicity. Cisplatin concentration in proximal tubular epithelial cells is about 5 times the serum concentration. Platinum exposure on renal tubular cells bonding covalent complex which stimulate production of inflammatory factors that lead to apoptosis and necrosis cell. Cisplatin nephrotoxicity can be prevented by aggressive hydration or alternate method of administration. The aim of this study was to analyze the effectiveness of NaCl-Mannitol hydration on renal function of head and neck cancer patients receiving cisplatin 100 mg/m2 chemotherapy combination with 5FU or paclitaxel. This was a cohort, prospective, and observational study to analyze renal function of head and neck cancer patients receiving cisplatin 100 mg/m2 chemotherapy combination with 5FU or paclitaxel. Inclusion criteria were BUN 7-18 mg/dl and serum creatinine < 2 mg/dl of any cycle. All patients received infuse NaCl-Mannitol hydration with term that provided in Surgeon Departement of Dr. Soetomo General Hospital. Data obtained were BUN, SCr, and eClCr Cockroft-Gault, each was measured pre- and post-hydration. In cisplatin and 5FU chemotherapy combination value BUN pre-hydration (11,99 + 4,62) mg/dl, value BUN post-hydration (12,14 + 4,74) mg/dl and value serum creatinine pre-hydration (0,97 + 0,34) mg/dl, value serum creatinine post-hydration (1,02 + 0,37) mg/dl. Meanwhile to the combination of cisplatin and paclitaxel chemotherapy, value BUN pre-hydration (10,19 + 2,58) mg/dl, value of BUN post-hydration (10,43 + 2,31) mg/dl and value of serum creatinine post- hydration (0,98 + 0,26) mg/dl. In conclusion, NaCl-Mannitol hydration administration is adequate which is shown by BUN and serum creatinine in pre- and post-hydration data within normal limits.

Title

Found 6 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 6 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 6 Documents
Search